TALS Stock Price History and Quote Analysis Insights for Investors
Talaris Therapeutics, Inc.
Stock Price Today
Talaris Therapeutics, Inc. (TALS) stock declined over -0.73%, trading at $2.72 on NASDAQ, down from the previous close of $2.74. The stock opened at $2.78, fluctuating between $2.69 and $2.80 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Company Information
| Employees | 84 |
| Beta | 2.18 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Talaris Therapeutics, Inc. (NASDAQ: TALS) stock price is $2.72 in the last trading session. During the trading session, TALS stock reached the peak price of $2.80 while $2.69 was the lowest point it dropped to. The percentage change in TALS stock occurred in the recent session was -0.73% while the dollar amount for the price change in TALS stock was -$0.02.
The NASDAQ listed TALS is part of Biotechnology industry that operates in the broader Healthcare sector. Talaris Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Nancy Krieger M.D.
Chief Medical Officer
Mr. Michael Zdanowski
Chief Technology Officer
Mr. Colby Suire Ph.D.
Head of R&D
Ms. Farah Natoli
Head of Portfolio & Program Management
Ms. Courtney Wells
Senior Vice President of Clinical Operations
Ms. Mary Kay Fenton
Interim Chief Executive Officer, Pres, Chief Financial Officer & Treasurer
Mr. Andrew Clyde Farnsworth
Chief HR Officer
Mr. Eric Gornstein
Senior Vice President of Strategy
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA
Pres, Chief Executive Officer, Sec. & Director
Mr. Devin Blass
Vice President of Technical Operations & Site Head
Dr. Suzanne T. Ildstad M.D.
Founder, Member of Scientific Advisory Board, Senior Scientific Advisor & Director
Ms. Suzanne Tollerud
Vice President of Corporation Devel.
TALS's closing price is 205.62% higher than its 52-week low of $0.89 where as its distance from 52-week high of $3.29 is -17.32%.
Number of TALS employees currently stands at 84.
Official Website of TALS is: https://talaristx.com
TALS could be contacted at phone 502 398 9250 and can also be accessed through its website. TALS operates from 570 South Preston Street, Louisville, KY 40202, United States.
TALS stock volume for the day was 303.48K shares. The average number of TALS shares traded daily for last 3 months was 142.92K.
The market value of TALS currently stands at $116.44M with its latest stock price at $2.72 and 42.81M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com